Cognition Therapeutics (CGTX) Other Non Operating Income (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Other Non Operating Income data on file, last reported at $4.2 million in Q1 2026.

• Quarterly Other Non Operating Income fell 19.79% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.3 million (up 14.38% YoY) and the FY2025 annual result came in at $24.3 million, up 21.59% from the prior year.
• Other Non Operating Income eased to $4.2 million in Q1 2026 per CGTX's latest filing, from $10.3 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $10.3 million in Q4 2025 and bottomed at $1.4 million in Q3 2025.
• The 5-year median for Other Non Operating Income is $5.5 million (2022), against an average of $5.6 million.
• Peak annual rise in Other Non Operating Income reached 258.49% in 2025, while the deepest fall reached 68.07% in 2025.
• Tracing CGTX's Other Non Operating Income over 5 years: stood at $4.1 million in 2022, then surged by 71.15% to $7.0 million in 2023, then plunged by 59.12% to $2.9 million in 2024, then surged by 258.49% to $10.3 million in 2025, then plunged by 58.88% to $4.2 million in 2026.
• Per Business Quant, the three latest CGTX Other Non Operating Income figures stand at $4.2 million (Q1 2026), $10.3 million (Q4 2025), and $1.4 million (Q3 2025).

Peer Comparison